Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend for Macular Edema in Central Retinal Vein Occlusion: the CENTERA Study

•From baseline to week 76, 65.6% of patients gained ?15 letters.•In the treat-and-extend phase, 45.0% achieved a mean treatment interval ?8 weeks.•A last actual weeks was by 63.1% patients.•Mean BCVA 51.9 letters at and 72.3 76 (+20.3 letters).•Mean central retinal thickness decreased from 759.9 µm 265.4 (?496.1 µm). PurposeTo evaluate efficacy safety intravitreal aflibercept (IVT-AFL) dosing in with macular edema secondary vein occlusion (CRVO).DesignCENTERA (Evaluation Treat Extend Regimen Intravitreal Aflibercept for Macular Edema Secondary CRVO; NCT02800642) an open-label, Phase 4 clinical study.MethodsPatients received 2 mg IVT-AFL every thereafter, until disease stability criteria were met (or 20), which point intervals adjusted 2-week increments based on functional anatomic outcomes.ResultsFrom 105 (65.6%) (P <.0001 [test against threshold 40%]) letters; and, during 72 (45.0%) = 0.8822 50%]) weeks. A next planned 101 (63.1%) 108 (67.5%), respectively. Mean ± SD best-corrected visual acuity increased 16.8 18.5 (mean change: +20.3 19.5 letters), 246.0 57.9 ?496.1 252.4 The profile consistent that previous studies.ConclusionsClinically meaningful improvements outcomes dosing. Most intended weeks; therefore, may have been extended even further longer study duration. To (CRVO). CENTERA study. Patients outcomes. From studies. Clinically